Ionis Pharmaceuticals Inc is a pioneer in creating RNA-targeted therapeutics. With a focus on serious and rare diseases, it has brought to market treatments like SPINRAZA for spinal muscular atrophy and TEGSEDI for polyneuropathy caused by hereditary transthyretin amyloidosis. The company is also advancing a robust pipeline of medicines targeting conditions such as amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B, among others. Ionis collaborates with leading pharmaceutical companies to enhance its reach and impact. Based in Carlsbad, California, Ionis continues to push the boundaries of medical science.
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high,…
Joel South Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Tuesday's top analyst upgrades and downgrades included BioNTech, ConocoPhillips, Harley-Davidson, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines, US Foods, Workday and Wells Fargo.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Chris Lange Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.
Chris Lange 
